LungenClinic Grosshansdorf

Perioperative Durvalumab for Resectable NSCLC : Updated Outcomes for Japanese Patients in AEGEAN

ABSTRACT In the phase 3 AEGEAN study, perioperative durvalumab plus neoadjuvant chemotherapy significantly improved the primary endpoints of event‐free survival (EFS) and pathological complete response (pCR) in patients with resectable NSCLC versus neoadjuvant chemotherapy alone....

Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

Abstract Despite a decade in, immunotherapy (IO) treatment selection in non-small cell lung cancer (NSCLC) remains largely guided by subgroup analyses and imperfect programmed death ligand 1 (PD-L1) and clinical scores. To our knowledge, I 3 LUNG ( NCT05537922 ) is currently the...